RJA
DARE icon

Raymond James & Associates’s Dare Bioscience DARE Stock Holding History

Raymond James & Associates’s Portfolio DARE Stock Details DARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,433
Closed -$17K – 3790
2020
Q3 		$17K Buy
+1,433
New +$19.1K ﹤0.01% 3515

Other funds holding DARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
FFS
Founders Financial Securities Towson, Maryland $1.77B AUM 17.63% 1-Year Est. Return

Raymond James & Associates's DARE Position: Q4 2020 in Review

Raymond James & Associates sold out of Dare Bioscience (DARE) in Q4 2020, closing a stake of 1,433 shares — an estimated $17K sold.

Raymond James & Associates first reported a position in DARE in Q3 2020 and held it in 1 quarter. The position peaked at $17K in Q3 2020. 27 funds tracked by Wall St. Rank hold DARE as of Q4 2020.

  • Raymond James & Associates reported no remaining Dare Bioscience position as of Q4 2020 after selling out during the quarter.
  • Raymond James & Associates sold 1,433 Dare Bioscience shares in Q4 2020, an estimated $17K.
  • Raymond James & Associates first reported a position in Dare Bioscience in Q3 2020 and held it in 1 quarter.
  • Raymond James & Associates's Dare Bioscience position peaked at $17K in Q3 2020.
  • 27 funds tracked by Wall St. Rank held Dare Bioscience as of Q4 2020.

Based on Raymond James & Associates's 13F filing for Q4 2020, filed 12 Feb 2021.